Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2026-09-01 21:00:30 ET · period of report 2026-08-28 · accession 0001140361-26-035375 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-01 21:00 | 2026-08-28 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.80M | +13% | +$770.0K |
| DMT | 2026-09-01 21:00 | 2026-08-28 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $35.77 | -200.0K | 1.60M | -11% | -$7.15M |
| DT | 2026-09-01 21:00 | 2026-08-28 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $0.00 | -200.0K | 3.84M | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-08-28 | M | A | 200,000 | $3.85 | 1,799,154 | D | — | — | |
| 2 | Common | Common Shares | 2026-08-28 | S | D | 166,182 | $35.63 | 1,632,972 | D | — | — | (F1) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.17 to $36.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. |
| 3 | Common | Common Shares | 2026-08-28 | S | D | 33,818 | $36.44 | 1,599,154 | D | — | — | (F2) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.17 to $36.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-08-28 | M | D | 200,000 | $0.00 | 3,844,834 | D | $3.85 · — to 2032-04-19 | 200,000 Common Stock | (F3) Reflects an award of stock options to purchase Common Shares that is fully vested. |